Our Services
Medical Information
Helpful Resources
Published on: 9/15/2026
Valacyclovir typically begins reducing pain, itching, and tingling within 24 to 48 hours, and most cold sore or recurrent genital herpes outbreaks heal in about 3 to 7 days when treatment starts at the very first symptoms, while a first-time genital outbreak or shingles can take 7 to 14 days or longer. Healing time varies based on several important factors, including how quickly you start the medication, your dose, whether it is an initial or recurrent episode, and your immune health. See below to understand more, including what can slow healing and when a lack of improvement means you should contact a clinician.
Because outbreak timelines overlap with other conditions that cause blisters, sores, and burning skin pain, guessing can delay the treatment window when antivirals work best. Take a free, instant, online symptom check to help clarify what may be causing your symptoms and get guidance on the right next steps.
Last reviewed for medical accuracy: 09/15/2025
Valacyclovir is one of the most commonly prescribed antiviral medications for treating herpes simplex virus (HSV) outbreaks, including cold sores (HSV-1) and genital herpes (HSV-2). Understanding how long it takes for valacyclovir to work—and what factors influence healing—can help you manage expectations and plan your treatment effectively.
Valacyclovir is a prodrug of acyclovir. Once ingested, your body converts valacyclovir into acyclovir, which then:
By stopping the virus from multiplying, valacyclovir helps the body’s immune system clear the infection more quickly, reducing pain, healing time, and the risk of spreading the virus to others.
Timing matters. To get the best results from valacyclovir, follow your doctor’s instructions closely:
Starting treatment within 24–48 hours of noticing symptoms (tingling, itching, redness) leads to faster healing.
While individual experiences vary, most people can expect the following general timeline when taking valacyclovir:
Day 1–2: Symptom Onset and Early Treatment
Day 3–5: Blister Formation and Peak Symptoms
Day 7–10: Crusting and Healing
Day 10–14: Complete Resolution
Key takeaway: For a first outbreak, valacyclovir usually helps sores heal within 7–10 days. Recurrent outbreaks treated promptly often heal in 3–5 days.
Healing times can differ based on:
Most people tolerate valacyclovir well. You might experience:
These side effects are usually mild and subside within a few days. Staying well-hydrated can help reduce the risk of kidney-related side effects, especially if you take higher doses.
While valacyclovir dramatically speeds healing for most people, you should speak to a doctor if you experience:
If any symptom feels life threatening or serious, seek medical help immediately.
In addition to taking valacyclovir, consider these measures:
If you have frequent outbreaks (more than six recurrences per year), talk to your doctor about suppressive therapy. Daily valacyclovir can:
Keeping a simple outbreak diary can help you and your doctor fine-tune treatment:
This information provides real-world data to guide future dosing and timing.
Not sure if your symptoms match a herpes outbreak? Before or during treatment, you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you understand your symptoms and decide whether you need in-person care.
Valacyclovir is a proven antiviral that typically heals first-time herpes outbreaks in 7–10 days and recurrent outbreaks in 3–5 days when started early. Factors such as immune health, outbreak severity, and how quickly you begin therapy influence your personal timeline. Most people tolerate valacyclovir well, with only mild side effects.
Always:
If you experience life-threatening or concerning symptoms, seek medical attention right away. And remember: a simple conversation with your doctor can ensure you’re using valacyclovir safely and effectively.
Speak to a doctor about any questions or concerns, especially if your symptoms worsen or you have difficulty taking your medication. Your healthcare provider knows your medical history best and can offer personalized guidance for managing outbreaks and staying healthy.
(References)
* Acosta EP, Fletcher CV. Valacyclovir. Ann Pharmacother. 1997 Feb;31(2):185-91. doi: 10.1177/106002809703100211. PMID: 9034421.
* Lebrun-Vignes B. [Valaciclovir]. Ann Dermatol Venereol. 2002 May;129(5 Pt 1):708-15. PMID: 12124513.
* Sacks SL, Griffiths PD, Corey L, Cohen C, Cunningham A, Dusheiko GM, Self S, Spruance S, Stanberry LR, Wald A, Whitley RJ. HSV-2 transmission. Antiviral Res. 2004 Aug;63 Suppl 1:S27-35. doi: 10.1016/j.antiviral.2004.06.005. PMID: 15450383.
* Arslan HH, Satar B, Yildizoglu U, Edizer DT, Akgun H. Validity of late-term electroneurography in Bell's palsy. Otol Neurotol. 2014 Apr;35(4):656-61. doi: 10.1097/MAO.0000000000000233. PMID: 24608371.
* Sénat MV, Anselem O, Picone O, Renesme L, Sananès N, Vauloup-Fellous C, Sellier Y, Laplace JP, Sentilhes L. Prévention et prise en charge de l’infection herpétique au cours de la grossesse et de l’accouchement : recommandations pour la pratique clinique – texte des recommandations (texte court). Gynecol Obstet Fertil Senol. 2017 Dec;45(12):705-714. doi: 10.1016/j.gofs.2017.10.007. Epub 2017 Nov 11. PMID: 29132768.
* Leruez-Ville M, Foulon I, Pass R, Ville Y. Cytomegalovirus infection during pregnancy: state of the science. Am J Obstet Gynecol. 2020 Sep;223(3):330-349. doi: 10.1016/j.ajog.2020.02.018. Epub 2020 Feb 24. PMID: 32105678.
* Prescott CR, Cohen EJ, Hochman JS, Troxel AB, Lu Y, Twi-Yeboah A, Jimenez CL, Mian SI, Mazen CY, Warner DB, Baratz KH, Jeng BH, ZEDS Trial Research Group. Baseline Participant Characteristics at Enrollment in the Zoster Eye Disease Study. Cornea. 2024 Dec 1;43(12):1473-1480. doi: 10.1097/ICO.0000000000003497. PMID: 38411973; PMCID: PMC11347717.
* Santhiago MR, Sampaio LP, Arroyo D, Wilson SE, Moshirfar M, Del Risco N, Moin KA, Cabanás M, Ruiz R, Llovet F, Shetty R, Nawas Z, Al-Mohtaseb Z, Pflugfelder SC, Chen AJ. Addressing corneal opacity after herpes zoster infection. J Cataract Refract Surg. 2024 Jun 1;50(6):655-659. doi: 10.1097/j.jcrs.0000000000001471. PMID: 38985933.
* Cohen EJ, Troxel AB, Liu M, Hochman JS, Baratz KH, Mian SI, Choulakian MY, Warner DB, Lu Y, Twi-Yeboah A, Lee TF, Kim J, Lopez-Jimenez C, Laury SC, Jeng BH, ZEDS Trial Research Group. Low-Dose Valacyclovir in Herpes Zoster Ophthalmicus: The Zoster Eye Disease Randomized Clinical Trial. JAMA Ophthalmol. 2025 Apr 1;143(4):269-276. doi: 10.1001/jamaophthalmol.2024.6114. PMID: 40048183; PMCID: PMC11886868.
* Mancini A, Inchingolo AM, Marinelli G, Trilli I, Sardano R, Pezzolla C, Inchingolo F, Palermo A, Dipalma G, Inchingolo AD. Topical and Systemic Therapeutic Approaches in the Treatment of Oral Herpes Simplex Virus Infection: A Systematic Review. Int J Mol Sci. 2025 Sep 1;26(17). doi: 10.3390/ijms26178490. Epub 2025 Sep 1. PMID: 40943411; PMCID: PMC12428954.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.